Kiniksa Pharmaceuticals, Ltd. - (KNSA) News

Kiniksa Pharmaceuticals, Ltd. - (KNSA): $11.83

0.19 (+1.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter KNSA News Items

KNSA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest KNSA News From Around the Web

Below are the latest news stories about Kiniksa Pharmaceuticals Ltd that investors may wish to consider to help them evaluate KNSA as an investment opportunity.

Greenberg Traurig Represents Huadong Medicine in Two Licensing Deals Totalling Over $1.6 Billion in Value

ATLANTA , March 3, 2022 /PRNewswire-PRWeb/ -- Wayne H. Elowe , co-chair of the Life Sciences and Medical Technology Group at global law firm Greenberg Traurig, LLP and co-chair of the firm''s Atlanta Corporate Practice, led the Greenberg Traurig team representing Huadong Medicine Co., Ltd., one of the leading pharmaceutical companies in China with a focus on oncology and Antibody-drug Conjugates research, development, and commercialization, on two large licensing deals, both of which closed in February 2022 . These deals mark the continuation of a longstanding relationship between Huadong Medicine and Greenberg Traurig Shareholders Elowe and Dawn (Dan) Zhang ( Shanghai ) who have represented Huadong in numerous transactions. In the first deal, Elowe advised Hangzhou Zhongmei Huadong Pha...

Benzinga | March 3, 2022

Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration

Collaboration includes rights to develop and commercialize ARCALYST ® and mavrilimumab in the Asia Pacific Region (excluding Japan) Kiniksa to receive $22 million upfront; eligible to receive development and commercial milestone payments and tiered royalties HAMILTON, Bermuda, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA ) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (Huadong Medicine), today announced a strategic collaboration to develop and commercialize Kiniksa''s ARCALYST ® and mavrilimumab in the Asia Pacific Region. "This collaboration aims...

Benzinga | February 22, 2022

Kiniksa Pharmaceuticals, Ltd. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 22, 2022

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -20.45% and 14.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

– ARCALYST® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 –– ARCALYST collaboration achieved profitability in Q4 2021 –– ARCALYST full-year 2022 net revenue expected to be $115 - $130 million –– Strategic collaboration with Huadong Medicine to develop and commercialize ARCALYST and mavrilimumab in the Asia Pacific Region (excluding Japan) –– Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Kiniksa P

Yahoo | February 22, 2022

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022

HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 22, 2022, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2021 financial results and corporate update.

GlobeNewswire | February 18, 2022

Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones

- ARCALYST® full-year 2022 guidance to be provided with Q4 2021 financial results -- Vixarelimab Phase 2b data in prurigo nodularis expected in 2H 2022 –- KPL-404 Phase 2 trial in rheumatoid arthritis now enrolling and dosing patients -- Year-end 2021 cash reserves expected to fund current operating plan into 2024 - HAMILTON, Bermuda, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of assets designed to modulat

Yahoo | January 10, 2022

Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

Yahoo | January 3, 2022

Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | January 3, 2022

Wall Street Analysts See a 151% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 150.6% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 31, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.533 seconds.